Evidence map›Paper›PMID 36070942›Full record

ArticleInternal medicine (Tokyo, Japan)2023

Autoimmune Pulmonary Alveolar Proteinosis with Suspected Exacerbation after Osimertinib Administration for Lung Cancer.

Masafumi Shimoda, Haruyuki Ishii, Yoshiaki Tanaka, Kozo Morimoto, Tamiko Takemura, Teruaki Oka, Kozo Yoshimori, Ken Ohta

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Masafumi ShimodaRespiratory Disease Center, Fukujuji Hospital, Japan Anti-tuberculosis Association, Japan.
Haruyuki IshiiDepartment of Respiratory Medicine, Kyorin University School of Medicine, Japan.
Yoshiaki TanakaRespiratory Disease Center, Fukujuji Hospital, Japan Anti-tuberculosis Association, Japan.
Kozo MorimotoRespiratory Disease Center, Fukujuji Hospital, Japan Anti-tuberculosis Association, Japan.
Tamiko TakemuraDepartment of Pathology, Kanagawa Cardiovascular and Respiratory Center, Japan.
Teruaki OkaDepartment of Pathology, Japan Anti-tuberculosis Association Fukujuji Hospital, Japan.
Kozo YoshimoriRespiratory Disease Center, Fukujuji Hospital, Japan Anti-tuberculosis Association, Japan.
Ken OhtaRespiratory Disease Center, Fukujuji Hospital, Japan Anti-tuberculosis Association, Japan.
Fukujuji Hospital · JPKanagawa Cardiovascular and Respiratory Center · JPKyorin University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 46-year-old woman with lung cancer who received chemotherapy was admitted to our hospital for lower-lobe bilateral ground-glass opacity (GGO). GGO developed after the lung cancer diagnosis, deteriorated after the initiation of osimertinib, and incompletely decreased after interrupting osimertinib; therefore, flexible bronchoscopy was performed. Transbronchial lung biopsy histology and anti-granulocyte/macrophage colony-stimulating factor autoantibody positivity revealed autoimmune pulmonary alveolar proteinosis (aPAP) that did not require treatment. This rare case of aPAP comorbid with lung cancer suggested that using PAP findings to differentiate from drug-induced lung injury or lymphangitis is difficult and that osimertinib was suspected to exacerbate aPAP.

Indexed as

Autoimmune DiseasesLung NeoplasmsPulmonary Alveolar ProteinosisAcrylamidesAniline CompoundsFemaleHumansIndolesLungMiddle AgedPyrimidinesAcrylamidesAniline CompoundsIndolesosimertinibPyrimidinesanti-granulocyte/macrophage colony-stimulating factor autoantibodylung cancerosimertinibpulmonary alveolar proteinosistyrosine kinase inhibitor

Identifiers

PMID36070942
PMCPMC10183281
OpenAlexW4294877959

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.